Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, accounting for 1 in 5 diagnoses.
1-3 Developments in ALL treatment have dramatically improved survival rates throughout the last 20 years.
4,5 Relapsed ALL has not seen the same advances, with 5-year survival rates of 20% to 60%, depending on relapse site and timing.
6,7 Treatment for high-risk, relapsed pediatric ALL has involved hematopoietic stem cell transplant (HSCT). Outside of HSCT, salvage regimens generally consist of adapted combinations of front-line therapies.
8 While HSCT was considered the only curative option in these high-risk situations, not all patients with relapsed ALL will be eligible for HSCT. Furthermore, HSCT is associated with significant morbidity and treatment-related mortality.
9,10 Both graft vs host disease (GVHD) and relapses after HSCT are common.
9,11,12 Hematopoietic stem cell transplant is also costly, with a first-year inpatient cost of almost CaD $230 000 (US $174 712) in Canada.
13